{"id":163584,"date":"2022-10-03T01:51:04","date_gmt":"2022-10-03T05:51:04","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/new-analysis-of-soloist-whf-trial-underscores-sotagliflozins-effect-on-reducing-recurrent-heart-failure-events\/"},"modified":"2024-08-18T11:45:26","modified_gmt":"2024-08-18T15:45:26","slug":"new-analysis-of-soloist-whf-trial-underscores-sotagliflozins-effect-on-reducing-recurrent-heart-failure-events","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/new-analysis-of-soloist-whf-trial-underscores-sotagliflozins-effect-on-reducing-recurrent-heart-failure-events.php","title":{"rendered":"New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin\u2019s Effect on Reducing Recurrent Heart Failure Events"},"content":{"rendered":"<p><![CDATA[THE WOODLANDS, Texas, Oct.  02, 2022  (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society of America (HSFA) Annual Scientific Meeting 2022.]]><\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/10\/02\/2526424\/0\/en\/New-Analysis-of-SOLOIST-WHF-Trial-Underscores-Sotagliflozin-s-Effect-on-Reducing-Recurrent-Heart-Failure-Events.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin\u2019s Effect on Reducing Recurrent Heart Failure Events\">New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin\u2019s Effect on Reducing Recurrent Heart Failure Events<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to see the original: New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin\u2019s Effect on Reducing Recurrent Heart Failure Events <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/new-analysis-of-soloist-whf-trial-underscores-sotagliflozins-effect-on-reducing-recurrent-heart-failure-events.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-163584","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/163584"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=163584"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/163584\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=163584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=163584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=163584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}